Kymera Therapeutics, Inc.
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$73.21
Price+2.69%
$1.92
1Y
Price
Market Cap
$6.022b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-195.4%
EBITDA Margin-201.5%
Net Profit Margin-259.8%
Free Cash Flow Margin-195.4%
EBITDA Margin-201.5%
Net Profit Margin-259.8%
Free Cash Flow MarginRevenue
$51.465m
+31.3%
1y CAGR-8.5%
3y CAGR+10.6%
5y CAGREarnings
-$315.053m
-1.2%
1y CAGR-30.9%
3y CAGR-21.9%
5y CAGREPS
-$3.58
+3.0%
1y CAGR-13.0%
3y CAGR-6.7%
5y CAGRBook Value
$1.540b
$1.669b
Assets$129.379m
Liabilities$80.469m
DebtDebt to Assets
4.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$243.997m
-4.1%
1y CAGR-22.7%
3y CAGR-14.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company